What is Wedbush's Forecast for APLS Q3 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at Wedbush issued their Q3 2026 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.22) for the quarter. Wedbush has a "Neutral" rating and a $29.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals' Q4 2026 earnings at ($0.14) EPS.

A number of other brokerages have also weighed in on APLS. The Goldman Sachs Group decreased their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Royal Bank of Canada dropped their price target on shares of Apellis Pharmaceuticals from $24.00 to $21.00 and set a "sector perform" rating on the stock in a report on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Scotiabank upped their price objective on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a "sector perform" rating in a research report on Wednesday, April 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $45.35.

Apellis Pharmaceuticals Stock Down 3.2 %

NASDAQ:APLS traded down $0.57 on Thursday, reaching $17.46. 1,385,276 shares of the stock traded hands, compared to its average volume of 2,004,370. The company's fifty day simple moving average is $23.51 and its 200 day simple moving average is $27.93. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -8.62 and a beta of 0.85. Apellis Pharmaceuticals has a 12 month low of $17.01 and a 12 month high of $50.98. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analysts' expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.73) earnings per share.

Insider Activity

In related news, General Counsel David O. Watson sold 5,569 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. The trade was a 3.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Timothy Eugene Sullivan sold 3,088 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $93,967.84. Following the sale, the chief financial officer now owns 129,211 shares of the company's stock, valued at approximately $3,931,890.73. This represents a 2.33 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,011 shares of company stock worth $1,059,969. 6.80% of the stock is currently owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently bought and sold shares of APLS. Boxer Capital Management LLC purchased a new stake in Apellis Pharmaceuticals during the 4th quarter valued at about $45,504,000. National Bank of Canada FI increased its holdings in Apellis Pharmaceuticals by 266,361.5% in the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock worth $44,214,000 after buying an additional 1,385,080 shares during the period. Royal Bank of Canada increased its holdings in Apellis Pharmaceuticals by 969.6% in the 4th quarter. Royal Bank of Canada now owns 1,518,827 shares of the company's stock worth $48,465,000 after buying an additional 1,376,832 shares during the period. Cibc World Markets Corp purchased a new position in Apellis Pharmaceuticals during the 4th quarter worth approximately $41,014,000. Finally, Point72 Asset Management L.P. acquired a new stake in Apellis Pharmaceuticals during the 4th quarter valued at approximately $40,461,000. Hedge funds and other institutional investors own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).